araag2/HINT huggingface dataset:
Clinical trial NCT02234141 (phase 2, status: completed)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: placebo, selonsertib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary
             arterial hypertension (HPAH), drug- and toxin-induced PAH, or PAH associated with
             connective tissue disease, human immunodeficiency virus (HIV) infection, or congenital
             heart defects (repaired greater than 1 year prior to Screening)

          -  Meet all of the following hemodynamic criteria by means of a screening right heart
             catheterization (RHC) completed prior to randomization:

               -  Mean pulmonary artery pressure (mPAP) of greater than or equal to (≥) 25
                  millimeters of mercury (mm Hg)

               -  Pulmonary vascular resistance (PVR) ≥ 400 dyne* second/centimeter^5
                  (dynes*sec/cm^5)

               -  Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic
                  pressure (LVEDP) of less than or equal to (≤) 12 mm Hg if PVR ≥ 400 and less than
                  (<) 500 dynes*sec/cm^5, or PCWP/LVEDP ≤ 15 mm Hg if PVR ≥ 500 dynes•sec/cm^5

          -  Be able to walk a distance of at least 100 meters

          -  Have World Health Organization (WHO) Functional Class II or III symptoms

          -  Meet the following criteria determined by pulmonary function tests completed no more
             than 24 weeks prior to screening, performed with or without bronchodilation:

               -  Forced expiratory volume in one second (FEV1) ≥ 55 percent (%) of predicted
                  normal

               -  FEV1: forced vital capacity (FVC) ratio ≥ 0.60

          -  Receiving treatment with one or more drugs approved for PAH for ≥ 12 consecutive weeks
             and at stable dose for ≥ 8 consecutive weeks

        Key Exclusion Criteria:

          -  Diagnosis of PAH associated with significant venous or capillary involvement (PCWP
             greater than [>] 15 mm Hg), pulmonary capillary hemangiomatosis, portal hypertension,
             or unrepaired congenital heart defects

          -  Pulmonary hypertension (PH) belonging to groups 2 to 5 of the 2013 NICE classification

          -  Left ventricular ejection fraction (LVEF) ≤ 40% or clinically significant ischemic,
             valvular or constrictive heart disease

          -  Uncontrolled hypertension (≥ 180/110 mm Hg) at Screening

          -  End stage renal disease (receiving peritoneal dialysis, hemodialysis, or status after
             renal transplantation)

          -  Severe liver disease (Child-Pugh Class C, with or without cirrhosis)

        Individuals may be rescreened one additional time with prior notification to and approval
        by the sponsor.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02235077 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: spironolactone, placebo
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patient ≥21 years old

          -  Admitted to hospital for AHF with at least 1 symptom (dyspnea, orthopnea, or fatigue)
             and 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular
             congestion on chest radiography) of congestion

          -  Patient must be randomized within 24 hours of first IV diuretic dose administered for
             the current episode of decompensation (regardless of where the diuretic was given e.g.
             office, ED, ambulance, hospital etc.)

          -  Estimated GFR of ≥30 mL/min/1.73m2 determined by the MDRD equation

          -  Serum K+ ≤5.0 mmol/L at enrollment

          -  NT-proBNP ≥1000 pg/mL or BNP ≥250 pg/mL, measured within 24h from randomization

          -  Not on MRA or on low-dose spironolactone (12.5 mg or 25 mg daily) at baseline

        Exclusion Criteria:

          -  Taking eplerenone or >25 mg spironolactone at baseline

          -  eGFR < 30 ml/min/1.73m2

          -  Serum K+ >5.0 mmol/L. If a repeat measurement within the enrollment window is <5.0,
             the patient can be considered for inclusion.

          -  Systolic blood pressure <90 mmHg

          -  Hemodynamically significant arrhythmias or defibrillator shock within 1 week

          -  Acute coronary syndrome currently suspected or within the past 4 weeks

          -  Severe liver disease (ALT or AST >3 x normal, alkaline phosphatase or bilirubin >2x
             normal)

          -  Active infection (current use of oral or IV antimicrobial agents)

          -  Active gastrointestinal bleeding

          -  Active malignancy other than non-melanoma skin cancers

          -  Current or planned mechanical circulatory support within 30 days

          -  Post cardiac transplant or listed for transplant and expected to receive one within 30
             days

          -  Current inotrope use

          -  Complex congenital heart disease

          -  Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis,
             constrictive pericarditis or tamponade

          -  Previous adverse reaction to MRAs

          -  Enrollment in another randomized clinical trial during index hospitalization
Clinical trial NCT02243202 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: canagliflozin, phentermine, matching placebo to canagliflozin, matching placebo to phentermine
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CC(C)(N)CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have BMI >=30 kg/m2 and <50 kg/m2 at screening or BMI >=27 kg/m2 and <50 kg/m2 at
             screening in the presence of a comorbidity of hypertension and/or dyslipidemia

          -  Must have stable weight, ie, change of < =5% in the 3 months before screening

          -  Must agree to utilize a highly effective method of birth control

        Exclusion Criteria:

          -  An established diagnosis of diabetes mellitus

          -  Has a history of obesity with a known secondary cause (eg, Cushing's disease/syndrome)

          -  Has a history of hereditary glucose-galactose malabsorption or primary renal
             glycosuria

          -  Myocardial infarction, unstable angina, revascularization procedure, or
             cerebrovascular accident within 12 weeks before screening

          -  Has an Glycated hemoglobin (HBA1c) greater than or equal (>=) to 65 percent

          -  An average of 3 seated blood pressure (BP) readings of systolic BP >= 160 mm Hg and/or
             Diastolic BP >= 100 millimeters of mercury at screening
Clinical trial NCT02244541 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: anavex2-73 oral, anavex2-73 intravenous, anavex2-73 oral, anavex2-73 oral
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Main Inclusion Criteria:

          1. Diagnosis of Probable AD in accordance with NINCDS-ADRDA criteria.

          2. A brain CT or MRI scan performed within last 12 months from day of screening
             consistent with the clinical diagnosis of probable AD.

          3. Age from 55 to 85 years inclusive.

          4. MMSE score of 16-28 inclusive.

          5. Rosen Modified Hachinski Ischemic score <=4.

          6. Community dwelling with caregiver who has regular contact with the subject for at
             least 10 hours per week and is able to oversee the patient's compliance with study
             medication and participate in the patient's clinical assessment and is capable of
             accompanying the participant on all clinic visits.

          7. Fluency in English.

          8. Be able to read, write, speak clearly for the cognitive tests, with eyesight and
             hearing sufficient to enable completion of the cognitive tests.

          9. Receiving stable doses of medications for the treatment of non-excluded medical
             conditions for at least 30 days prior to screening.

        Main Exclusion Criteria:

          1. Dementia other than AD such as AIDS, CJD, LBD, CVD, Progressive Supranuclear Palsy,
             Multiple cerebral infarcts, or normal pressure hydrocephalus.

          2. Other neurodegenerative diseases, including Parkinson's disease and Huntington's
             disease, or cerebral tumour.

          3. Current presence of a clinically significant major psychiatric disorder according to
             the criteria of the DSM-IV, or symptom that could affect the participant's ability to
             complete the study). HAM-D score >12.

          4. Current clinically significant systemic illness that is likely to result in
             deterioration of the patient's condition or affect the patient's safety during the
             study.

          5. Any other criteria which in the opinion of the Investigator causes the participant not
             to qualify for the study.
Clinical trial NCT02244944 (phase 2, status: terminated)
Conditions: nonalcoholic fatty liver disease (nafld)
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: ez-urso combination therapy
SMILES: [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O
Reason stopped: 
    failure to recruit
  
Eligibility criteria:

        Inclusion Criteria:

          -  Steatosis

          -  ALT >1.5 times normal

          -  ALT/AST ratio >1.0

          -  Normal Kidney Function

        Exclusion Criteria:

          -  Normal ALT within last 6 months

          -  Advanced fibrosis based on 1) biopsy, if available (Stage 3 or 4 NAFLD), 2) imaging,
             or 3) lab (platelet count <150,000)

          -  Daily alcohol use above 20 g/day for women and 30 g/day for men

          -  Prescription use of ursodiol, ezetimibe, vitamin E, fish oils, thiazolidinediones,
             insulin, sulfonylureas, HMG-CoA reductase inhibitors

          -  Weight loss greater than 15% in past 12 months

          -  Pregnant or breastfeeding

          -  Body Mass index greater than 50

          -  Largest body circumference greater than 160 cm

          -  Claustrophobia

          -  Allergy to ezetimibe or ursodiol
Clinical trial NCT02245022 (phase 2/phase 3, status: completed)
Conditions: hiv, pregnancy
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, O00.00, O00.01, O00.101, O00.102, O00.109, O00.111, O00.112
Drugs: dolutegravir 50mg od, standard of care
SMILES: [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Able to provide informed consent

          -  Willing to participate,

          -  Women age 18 years and above

          -  Pregnant

          -  Untreated HIV infection in late pregnancy at ≥28 - 36 weeks gestation

        Exclusion Criteria:

          -  Received antiretroviral drugs in previous 6 months

          -  Ever received integrase inhibitors

          -  Serum haemoglobin < 8.0 g/dl

          -  Elevations in serum levels of alanine aminotransferase (ALT) >5 times the upper limit
             of normal (ULN) or ALT >3xULN and bilirubin >2xULN (with >35% direct bilirubin)

          -  eGFR < 50ml/min

          -  Active Hepatitis B infection, history or clinical suspicion of unstable liver disease,
             or subjects with severe liver disease (Class C by Childs-Hugh criteria)

          -  Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or
             liver abnormalities (e.g. grade 2 or above proteinuria, elevation in serum creatinine
             (above 2.5 x ULN), total bilirubin ALT or AST)

          -  Paternal non-consent (where disclosure to male partner has been made)

          -  Clinical depression or clinical judgement suggests increased risk of suicidality
Clinical trial NCT02246673 (phase 2, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: rdea3170 15 mg, rdea3170 10 mg, rdea3170 2.5, rdea3170 5 mg, febuxostat 40 mg, febuxostat 80 mg
SMILES: CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O, CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O, CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O, CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Able to understand the study procedures and the risks involved and is willing to
             provide written informed consent before the first study-related activity.

          -  Meets one or more criteria for the diagnosis of gout as per the American Rheumatism
             Association Criteria for the Classification of Acute Arthritis of Primary Gout.

          -  Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 45 kg/m2.

          -  Screening serum urate level ≥ 8 mg/dL.

          -  Free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Unable to take colchicine for gout flare prophylaxis.

          -  History or suspicion of kidney stones.

          -  Any gastrointestinal disorder that affects motility and/or absorption.

          -  Unstable angina, New York Heart Association class III or IV heart failure, ischemic
             heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or
             subject is currently receiving anticoagulants.

          -  Screening laboratory parameters that are outside the normal limits and are considered
             clinically significant by the Investigator.

          -  Estimated creatinine clearance < 60 mL/min calculated by the Cockcroft-Gault formula
             using ideal body weight during the Screening period.

          -  Taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2
             inhibitors; chronic and stable doses are permitted if doses are stable for at least 14
             days prior to study medication dosing.

          -  Unable or unwilling to comply with the study requirements or has a situation or
             condition that, in the opinion of the Investigator, may interfere with participation
             in the study.
Clinical trial NCT02249988 (phase 2/phase 3, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: abx203 therapeutic hepatitis b vaccine treatment arm
SMILES: [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject between 18 and 65 years of age at the time of randomization.

          -  Must be HBeAg negative and anti-HBe Abs positive for at least 1 year prior to
             screening and at screening.

          -  Has HBV DNA < 40 IU/mL for at least 1 year prior to screening and at screening

          -  Has both ALT and AST levels ≤ ULN for at least 1 year prior to screening and at
             screening.

          -  Must be HBsAg positive at screening.

          -  Has been treated with NUCs for at least 2 years prior to screening.

          -  Has not been treated with PEG-IFN or IFN for at least 1 year prior to screening.

          -  For all females, must have a negative serum pregnancy test at screening. For female of
             childbearing potential, must have been using adequate contraception and must agree to
             continue to use it during all study period and for 6 months after completion of the
             study product administration.

          -  Has provided written informed consent.

        Exclusion Criteria:

          -  Has elevated blood levels of alpha-fetoprotein (AFP) (> 500 ng/mL).

          -  Has cirrhosis, defined as

               -  platelet count < 150,000/mm3, with esophageal varices on imaging and spleen size
                  > 12, or

               -  liver stiffness of 11 kilopascal [kPa] as measured by elastography using
                  FibroScan® or .an AST to Platelet Ratio Index (APRI) > 2).

          -  Has hepatocellular carcinoma (HCC) (diagnosed by ultrasonography).

          -  Has liver decompensation (albumin < 3.5 g/dL and bilirubin ≥1.3 mg/dL).

          -  Is Hepatitis C virus (HCV) Ab positive at screening.

          -  Is Hepatitis delta virus (HDV) Ab positive at screening.

          -  Is Human Immunodeficiency Virus (HIV) Ab positive at screening.

          -  Has an immune suppressive disorder or treatment with immunosuppressive drugs.

          -  Has been treated with corticosteroids within 12 weeks prior to the first
             administration of study product, with the exception of topical or inhaled
             corticosteroids.

          -  Has been treated with rituximab.

          -  Has other hepatic diseases of different etiology (such as auto-immune hepatitis, toxic
             hepatitis, Wilson disease, alcoholic or hemochromatosis).

          -  Has a history of allergic disease or reactions likely to be exacerbated by any
             component of the study products.

          -  Has a history of a substance abuse (drug or alcohol) problem within the previous 3
             years.
Clinical trial NCT02250612 (phase 2, status: completed)
Conditions: open angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: 1 drop of 0.375% syl040012 (bamosiran), 1 drop of 0.750% syl040012 (bamosiran), 1 drop of 1.125% syl040012 (bamosiran), 1 drop of 1.5% syl040012 (bamosiran), 1 drop of 0.5 % timolol maleate
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients older than 18 years of either sex

          -  Good or fair general health as assessed by the investigator.

          -  Signed informed consent prior to any clinical trial-related procedures

          -  Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)

          -  Post-washout mean IOP above target range

          -  BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200)

          -  Stable visual field

          -  Central corneal thickness 480-620 μm

          -  Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Females of childbearing potential not willing to use a medically acceptable
             contraceptive method

          -  Clinically significant systemic disease

          -  Changes of systemic medication that could have a substantial effect on IOP

          -  Known hypersensitivity to any component of the formulations

          -  Unable to comply with the clinical trial requirements

          -  Clinically significant abnormalities in laboratory tests

          -  Severe visual field defect

          -  Any secondary glaucoma

          -  Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow
             angles.

          -  IOP ≥ 35 mm Hg in any eye

          -  Previous non-laser glaucoma surgery or glaucoma laser procedures (e.g., laser
             trabeculoplasty) and refractive surgery

          -  Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6
             months prior to Baseline

          -  Evidence of ocular infection, inflammation, clinically significant blepharitis or
             conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis

          -  Clinically significant ocular disease
Clinical trial NCT02251717 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Genotype 1 or 4 chronic HCV infection

          -  Have received a kidney transplant more than 6 months before the Baseline visit

          -  Cirrhosis determination

          -  Screening laboratory parameters within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Key Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain
             -resolved skin cancers)

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  Planned or anticipated second kidney transplant

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02252536 (phase 2, status: completed)
Conditions: alcohol use disorder
ICD codes: F10.94, F10.980, F10.982, F10.988, F10.99, F10.959, F10.96
Drugs: gabapentin enacarbil, placebo
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects must meet each one of the following inclusion criteria in order to be eligible for
        participation in the study:

          1. Be at least 21 years of age.

          2. Have a current (past 12 months) DSM-5 diagnosis of AUD.

          3. Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent
             document (either just prior to or immediately after signing consent).

          4. Be seeking treatment for problems with alcohol.

        Additional will be evaluated in clinic.

        Exclusion Criteria:

        Evaluations will be conducted in clinic.
Clinical trial NCT02252926 (phase 2, status: completed)
Conditions: mucositis
ICD codes: J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, K12.31
Drugs: bupivacaine, standard treatment (lidocaine viscous solution, morphine, paracetamol, nsaid, gabapentin)
SMILES: CC1=CC(O)=CC(C)=C1Cl, NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosed with head/neck cancer and starting radio therapy treatment

          -  age between 18 and 80 years (both included)

          -  able to talk, read and understand Danish

          -  ability to give informed consent

        Exclusion Criteria:

          -  known hypersensitivity towards bupivacaine or other local anesthetics of the amide
             type

          -  pregnancy

          -  women breastfeeding a child